GLP-1s, should we all be taking them?

GLP-1 agonists have gone from niche diabetes drugs to one of the most talked-about tools in modern medicine. In this episode of Longevity Technology Unlocked, Phil Newman and Dr. Nina Patrick are joined by two of the world’s leading authorities to unpack what this class of drugs really means for longevity, healthspan, and preventive care.

Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging, and Dr. Jens Juul Holst, the scientist who co-discovered the GLP-1 hormone, bring decades of research and clinical insight to a conversation that cuts through the hype and looks at the real science.

Together, they explore how GLP-1 agonists work in the body, why they are reshaping obesity and metabolic disease treatment, and whether their effects extend beyond weight loss into aging biology, inflammation, cardiovascular health, and even brain function.

This episode also dives into the uncomfortable but important questions. Should healthy people consider GLP-1s for longevity? Are microdosing trends and off-label use risky or inevitable? What do recent Alzheimer’s trial results actually tell us, and what comes next for brain health research?
Beyond GLP-1s, the discussion opens up into the broader future of longevity medicine, from insulin resistance and inflammation to biotech innovation, prevention-focused healthcare, and why aging itself may soon be treated as a modifiable condition rather than an inevitability.

In this episode, you’ll learn:

What GLP-1 agonists actually do in the body and why they took decades to reach mainstream use
Why obesity, insulin resistance, and aging are deeply connected at the biological level
How GLP-1s may influence cardiovascular risk, inflammation, and metabolic aging independent of weight loss
What recent Alzheimer’s and brain health studies really mean for neuroprotection
The risks, side effects, and realities behind microdosing and off-label use
Why prevention may become the next major frontier for biotech and pharma
How longevity medicine could shift healthcare away from blame, shame, and late-stage disease treatment